ArticleMovement disorders clinical practice
Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort.
Article in Movement disorders clinical practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 121 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Cilostazol on the Clinical Outcome of Patients with Parkinson's Disease
TALLman Family Energizes Research To Help Alleviate Neuroinflammation in Parkinson's Disease - "TALLER THAN PD." A Phase 2 Futility Study to Evaluate the Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Early Treated Parkinson's Disease
Who cites it
121 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.Clinical pharmacology and therapeutics · 2026Pooled it
- Devices for remote continuous monitoring of people with Parkinson's disease: a systematic review and cost-effectiveness analysis.Health technology assessment (Winchester, England) · 2024Pooled it
- Rate of motor progression in Parkinson's disease: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.Nature medicine · 2026Trial
- Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial.Movement disorders : official journal of the Movement Disorder Society · 2025Trial
- Boswellic acids as an adjunct therapy in Parkinson's disease: a double-blind clinical trial investigating on its effects on motor symptoms and inflammatory markers.Inflammopharmacology · 2025Trial
- Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.Nature medicine · 2024Trial
- Validating new symptom emergence as a patient-centric outcome measure for PD clinical trials.Parkinsonism & related disorders · 2024Trial
- Promoting independence in Lewy body dementia through exercise: the PRIDE study.BMC geriatrics · 2022Trial
- Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item-score models.CPT: pharmacometrics & systems pharmacology · 2021Trial
- A Pilot Study of VGGish-CNN as a Model for the Classification of Parkinson's Disease from a Control Group Using Speech Impairment, Integrated with Explainable Artificial Intelligence.Bioengineering (Basel, Switzerland) · 2026Article
- Associations of epigenetic age acceleration with motor impairment: Evidence from the Parkinson's Progression Markers Initiative cohort.Neurobiology of aging · 2026Article
- Long-Duration Response to Levodopa in the PPMI-Cohort.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- One-Year Substantia NigraMovement disorders : official journal of the Movement Disorder Society · 2026Article
- Cognitive structure and progression in Parkinson's disease: insights from a tablet-based assessment.Scientific reports · 2026Article
- Changes in Saccadic Hypometria over Time to Monitor Parkinson's Disease Progression.Pharmaceutical medicine · 2026Observational
- Therapeutic effects of cannabinoids on Parkinson's disease: an updated systematic review and meta-analysis of randomized controlled trials.Acta neurologica Belgica · 2026Review
- Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations.Acta pharmaceutica Sinica. B · 2026Review
- Correlations Between Clinical, Anthropometric and Nutritional Evaluations in Patients with Parkinson's Disease from Ghana: A Cross-Sectional Study.Journal of clinical medicine · 2026Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UDPRS) is a commonly used tool to measure Parkinson disease (PD) progression. Longitudinal changes in MDS-UPDRS scores in
objectiveDetermine progression rates of MDS-UPDRS scores in
methods362 participants from the Parkinson's Progression Markers Initiative, a multicenter longitudinal cohort study of
resultsMDS-UPDRS scores increased in a linear fashion over five years in
conclusionsThe expected average progression of MDS-UPDRS scores in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.